We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Antares Pharma Announces the Issuance of a New U. S. Patent for OTREXUP™
News

Antares Pharma Announces the Issuance of a New U. S. Patent for OTREXUP™

Antares Pharma Announces the Issuance of a New U. S. Patent for OTREXUP™
News

Antares Pharma Announces the Issuance of a New U. S. Patent for OTREXUP™

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Antares Pharma Announces the Issuance of a New U. S. Patent for OTREXUP™"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Antares Pharma, Inc. announced that it has received a Notice of Issuance from the U. S. Patent Office for patent number 8,480,631 entitled “Hazardous Agent Injection System.” The claims of this patent are directed toward an injection system for methotrexate and also a method for treating rheumatoid arthritis and other autoimmune diseases using an auto-injector or similar device for subcutaneous delivery of methotrexate. Upon its issuance on July 9, 2013, the patent will provide nearly seventeen (17) years of intellectual property protection for OTREXUP™.

 “This patent issuance represents a major milestone in our long-term strategy intended to provide comprehensive intellectual property protection for OTREXUP™,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer and co-inventor of the patent. “The granting of this broad and comprehensive patent is an important achievement in our commercialization strategy and one of a number of patent applications we have filed addressing the use of an auto-injector platform in combination with a wide range of product candidates, including those in our growing pipeline, such as QST being developed for testosterone replacement therapy.”

Advertisement